Valuation: RAPT Therapeutics, Inc.

Market Cap 939M 856M 788M 717M 1.35B 86.97B 1.42B 9.6B 3.81B 47.41B 3.52B 3.45B 149B P/E 2023
-8.16x
P/E 2024 -0.5x
Enterprise Value 712M 649M 598M 544M 1.02B 65.97B 1.08B 7.28B 2.89B 35.97B 2.67B 2.61B 113B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
96.87%
Yield 2023 *
-
Yield 2024 -
1 day+0.07%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 26.5
Extreme 26.5
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 03/03/2026
Treasurer - 03/03/2026
Director TitleAgeSince
Director/Board Member - 03/03/2026
Director/Board Member - 03/03/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/03/26 Tender

Chief Technology Officer

164,742 0.5945%
03/03/26 Tender

Chief Financial Officer

205,703 0.7423%
03/03/26 Tender

Director

59,858 0.2160%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+104.87%-48.71% 1.79B
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-2.19%-6.02%+10.50%+109.19% 45.66B
-1.89%-9.33%+13.03%+20.04% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.11%-8.59%+128.56%+655.74% 34.48B
-0.80%-1.73%+75.29%+56.47% 32.5B
-2.17%+19.70%-30.57%+469.42% 31.69B
Average -1.23%-0.58%+40.35%+154.41% 40B
Weighted average by Cap. -1.48%-1.27%+31.95%+150.52%

Financials

2023 2024
Net sales - -
Net income -117M -107M -98.06M -89.26M -167M -10.82B -177M -1.19B -474M -5.9B -438M -429M -18.51B -130M -118M -109M -99.24M -186M -12.03B -196M -1.33B -527M -6.56B -487M -477M -20.59B
Net Debt -152M -139M -128M -116M -218M -14.08B -230M -1.55B -617M -7.68B -570M -558M -24.09B -227M -207M -190M -173M -325M -20.99B -342M -2.32B -920M -11.44B -850M -832M -35.91B
Projected Income Statement - Annual - RAPT Therapeutics, Inc.
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock